Investigation into changes of the serotonin transporter (5-HTT) gene promoter in association with in vivo prefrontal 5-HTT availability and reward function in human obesity by Drabe, Mandy
 Investigation into epigenetic changes of the serotonin 
transporter (5-HTT) gene promoter in association with in 
vivo prefrontal 5-HTT availability and reward function in 
human obesity 
 
Dissertation 
zur Erlangung des akademischen Grades 
Dr. rer. med. 
 
an der Medizinischen Fakultät 
der Universität Leipzig 
        
 
 
eingereicht von: 
Diplom-Biologin Mandy Drabe, geb. Drabe 
 
geboren am 23. Juni 1984 in Leipzig 
 
angefertigt an der: 
Universität Leipzig, Klinik und Poliklinik für Nuklearmedizin 
 
Betreuer: 
Prof. Dr. med. Swen Hesse 
 
Beschluss über die Verleihung des Doktorgrades vom:21.08.2018 
 2 
 
Table of Contents 
 
Introduction ........................................................................................................................... 3 
Homeostatic and hedonic control of food intake ................................................................ 3 
The obesity epidemic ........................................................................................................ 4 
The role of 5-HT in energy balance ................................................................................... 5 
The role of 5-HT in the PFC function ................................................................................. 6 
The role of the PFC in food intake ..................................................................................... 7 
The association between central 5-HT transporter (5-HTT) availability and obesity ........... 7 
Genetics of obesity ............................................................................................................ 8 
Epigenetics of obesity ....................................................................................................... 9 
Objectives and hypothesis of the present work................................................................ 11 
Manuscript .......................................................................................................................... 12 
Summary ............................................................................................................................ 20 
References ......................................................................................................................... 22 
Appendices ............................................................................................................................ I 
Glossary ............................................................................................................................. I 
Publications ...................................................................................................................... IV 
Selbstständigkeitserklärung............................................................................................... V 
Danksagung ..................................................................................................................... VI 
 
  
 3 
Introduction 
Homeostatic and hedonic control of food intake   
Food intake is regulated by the interaction of two pathways: the homeostatic and hedonic 
pathway1. During each meal, the homeostatic pathway serves to limit energy intake in order 
to keep reserves balanced2, 3. The homeostatic pathway also controls energy balance by 
doing the opposite: raising the need to eat when energy stores are low1. 
Energy homeostasis and body weight are controlled by neuronal circuits in the 
hypothalamus and the brainstem4. The hypothalamus represents a key neuronal structure 
for integration of long-term adiposity signals such as leptin and insulin5. It also responds to 
short-term signals such as ghrelin which plays a role in meal initiation6. Leptin is synthesized 
by adipocytes and has the ability to act on neurons of the hypothalamic arcuate nucleus 
(Arc) to suppress food intake1. It has also been shown, that leptin decreases body weight by 
activating the sympathetic nervous system resulting in increased energy expenditure and 
thermogenesis7. Additionally, leptin exerts various beneficial effects on the glucose 
homeostasis by decreasing insulin resistance with associated hyperinsulinemia and 
hyperglycemia8. Insulin also suppresses appetite and promotes thermogenesis by 
interacting with insulin receptors expressed in hypothalamic neurons5.  
By increasing the demand to consume palatable foods, the homeostatic pathway can be 
overridden by the hedonic or reward-based regulation pathway during periods of energy 
abundance1. Here, leptin, insulin and ghrelin also convey information about energy reserves 
and thus, regulate central neuronal reward circuits involving several neurotransmitters such 
as dopamine (DA) and serotonin (5-hydroxytryptamine, 5-HT) and, in that way, the hedonic 
value of food9.  
Highly palatable foods produce positive emotional reactions which have been associated 
with eating disorders and obesity10. For example, the study of Choi et al. revealed 
interactions between reward and threat processing in regions of the prefrontal cortex (PFC) 
i.e. the middle frontal gyrus, but also in other distinct brain regions11 such as the nucleus 
accumbens (NAcc), a key neural substrate in the reward system due to its involvement in 
natural (i.e. food) reinforcement12.  
There are reports of direct and indirect interaction between the DA pathway and various 
peripheral metabolic signals13. For instance, leptin and insulin both inhibit DA neurons while 
ghrelin activates them13.  
Recently, several imaging studies have shown in humans that changes in the level of these 
peptides and/or neurotransmitters such as DA affect the motivation to eat by recruiting 
distinct brain areas. For example, the magnetic resonance imaging (MRI) study of Malik et 
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al. showed, that infusion of ghrelin results in enhanced activation of food cues in brain areas 
such as the amygdala, orbitofrontal cortex, anterior insula, and striatum that are involved in 
incentive and hedonic responses in healthy subjects14. By performing a positron emission 
tomography (PET) study with [18F]FDG (which is a marker of brain glucose metabolism), 
Anthony et.al showed that insulin resistance in the brain involves regions associated with 
reward such as the striatum and the PFC15. An fMRI study performed in leptin-deficient 
humans revealed, that leptin reduces food reward and increases the response to satiety 
signals that have been generated during food consumption caused by the modulation of 
neuronal activity in the striatum16 which has strong connection to PFC. In conclusion, the 
complementary action of leptin and insulin are capable to modify the DA pathway and thus, 
alter eating patterns13. 
Several studies performed in rodent models and humans confirmed the involvement of DA in 
overeating and obesity13, 17-22. The study of Stöckel et.al demonstrated differences in 
activation of brain regions in response to pictures of energy-dense food21. Here, normal-
weight women exhibit a significant activity increase in the dorsal striatum whereas obese 
women showed an increased activation in various limbic regions suggesting for an altered 
evaluation of food reward21. Taken together, those studies helped to characterize the effects 
of the well-established human brain DA system on eating patterns. However, further studies 
investigating the influence of 5-HT on energy balance and eating behavior plays also an 
important role since data to central 5-HT associated to in vivo measurements in human 
obesity are lacking. 
 
The obesity epidemic 
The World Health Organization (WHO) defines obesity as an abnormal or excessive amount 
of fat accumulation that affects health23. Indirect measurements such as waist 
circumference, waist/hip ratio, skin-fold thickness, bio impedance and body mass index 
(BMI) are used to categorize obesity,24 which for the latter metric, is set by the WHO as a 
value greater than 30 kg/m2 25. 
Obesity rates have dramatically risen worldwide in recent decades, affecting all sex, age and 
ethnic categories25. In the last fifty years alone, obesity rates have generally tripled, including 
in the United States25, where it causes approximately 300.000 preventable deaths each 
year24. Obesity is a major risk factor for various diseases such as type 2 diabetes, 
cardiovascular diseases, dyslipidemia, hypertension and several forms of cancer making it a 
serious healthcare problem 24, 25. The development of new therapies to counteract obesity 
therefore, represents an important target of current medical research26, 27. 
 5 
Weight gain is caused by an energy imbalance when caloric intake chronically exceeds 
caloric expenditure28. Numerous factors such as an environment with easy access to 
energy-dense foods, biological dysfunctions, genetic susceptibility, psychosocial factors, and 
lifestyle preferences are known to contribute to obesity, but their interaction is not yet fully 
understood29. 
There is emerging evidence that neurobiological mechanisms play a pivotal role in the 
pathogenesis of obesity30. It has been shown for example that neuropsychiatric drugs are 
capable of inducing weight gain27 and that obesity is mediated by learned behavior and may 
therefore be better understood by studying disciplines associated with cognition and 
behavior31-34. Several studies have reported an association between neurobehavioral 
changes such as emotional eating behavior induced by stress35-37 as well as altered reward 
processing with obesity10, 38. These associations involve an altered hypothalamic-pituitary-
adrenal (HPA) axis and other factors such as disturbed insulin sensitivity and glucose 
metabolism mediated by hypothalamic neuropeptides, adipokines as well as by appetite-
related hormones36. 
 
The role of 5-HT in energy balance  
5-HT is synthesized in the brainstem raphe nuclei, which deliver 5-HT throughout the CNS39. 
This includes the brainstem, the spinal cord and regions important for energy balance i.e. 
the nucleus of the solitary tract40, the parabrachial nuclei40, the amygdala, the striatum, the 
hippocampus, the PFC and of course hypothalamic regions such as the paraventricular 
nucleus (PVN) and the Arc41-43. 5-HT functions as a modulatory neurotransmitter to 
coordinate various cognitive, autonomic and other functions to maintain homeostasis44. 
Thus, 5-HT plays a crucial role in the regulation of energy balance44. 5-HT is synthesized 
from L-tryptophan, catalyzed by two enzymes: tryptophan decarboxylase and the tryptophan 
hydroxylase (TPH) and signals through eighteen 5-HT receptors that are distributed 
throughout the nervous system and peripheral organs39, 45 and have been classified into 
seven subfamilies: 5-HT1 to 5-HT7, which comprises 14 receptor subtypes associated with 
unique genes. With the exception of one receptor, the 5-HT3 receptor, a ligand-gated cation 
channel, all couple to G-protein coupled receptors46, 47. Within the hypothalamus the 5-HT2C 
receptor subtype (5-HT2C R) is highly expressed48. The signaling of 5-HT2C R plays a crucial 
role in energy balance. Studies demonstrated that the non-specific serotonin receptor 
agonist m-chlorophenylpiperazine (mCPP) with high affinity at 5-HT2CRs decreased 
feeding49, 50. This effect was reversible by blocking with non-selective antagonists49, 50. 
Similar findings were obtained in studies conducted with animal models, i.e with the 5HT2CR 
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knock-out mice lacking functional 5-HT2CRs. 5-HT2CR knock-out mice exhibit chronic 
hyperphagia followed by late onset of obesity39. Furthermore, it has been shown that they 
exhibit reduced sensitivity to the anorectic drug dexfenfluramine51. Remarkably, restoring the 
5-HT2CR in Arc pro-opiomelanocortin (POMC) neurons of these mice is sufficient to reverse 
obesity and restore the appetite-suppressing effects of dexfenfluramine52. 
It appears that the net effect of 5-HT signaling is that of suppression of food intake39. Acute 
inhibition of raphe nuclei by raphe injection of muscimol, a gamma-aminobutyric acid 
receptor A (GABA-A) agonist, results in hyperphagia and obesity39, 53, 54. In addition, 
perturbation of 5-HT synthesis by injection of the 5-HT neurotoxin 5,7-dihydroxytriptamine 
(5,7-DHT) have been also associated with hyperphagia55, 56. In contrast, central injection of 
5-HT or its precursor 5-hydroxytryptophan (5-HTP) has been demonstrated to result in an 
increased metabolic rate39, 57 and hypophagia39, 58-60.  
Various new weight-loss drugs have been approved for the use in the USA, while in Europe, 
they are not available61. The appetite suppressant fenfluramine elevates synaptic 5-HT 
concentrations by including vesicular release and inhibiting reuptake and thus, results in 
hypophagia57, 58, 62 and in an increased metabolic rate39. The sympathomimetic amine 
phentermine, an anorectic agent, is known to reduce appetite and is capable to induce a 
negative energy balance in some people63 However, these weight-loss drugs have been 
abandoned from the market due to serious toxic effects with high risk for valvulopathy, 
stroke, suicidal ideation and behavior, and myocardial infarction63. Lorcaserin, a selective 
agonist of the 5-HT2C receptor decreases food intake and body weight in a dose-dependent 
manner64. As a result of a successful phase III clinical trial, in which patients lost 5% body 
weight after 1 year of treatment65, lorcaserin is one of six currently FDA-approved drugs 
marketed for the treatment of obesity.  
 
 
The role of 5-HT in the PFC function  
Reward-related brain regions are interconnected with 5-HT containing neurons66. The 5-HT 
system consists of neurons, whose cell bodies form several nuclei located at the midline of 
the mesencephalon and medullary brainstem. Among them, two superior nuclei, the dorsal 
and median raphe nucleus, project to a range of limbic and forebrain regions such as the 
PFC66.  
The PFC is a cortical region which encompasses the most anterior structures of the frontal 
lobe and is densely expressed with 5-HT receptors46. In this region, 5-HT1A and 5-HT2A 
receptors are selectively expressed in distinct populations of pyramidal neurons and 
inhibitory interneurons and play an important role in modulating cortical activity and neuronal 
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oscillations46. 5-HT1A receptors are known to be inhibitory, whereas 5-HT2A are excitatory in 
nature46. Both receptor types are differentially distributed in cellular compartments. 5-HT1A is 
densely
 
expressed in pyramidal neurons to suppress the generation of action potentials. 
However, 5-HT2A receptors are present in apical dendrites where they amplify the impact of 
excitatory synaptic currents46. 5-HT receptors have also been found to be expressed at axon 
terminals in the cortex. Here, they are able to regulate impulse-dependent release of GABA 
and glutamate46. 
Experiments in rodents confirmed, that 5-HT neurons located in the dorsal and median 
raphe nuclei send axons to various sub-regions of the PFC such as the infralimbic cingulate 
and prelimbic cortices46. Retrograde and anterograde tracing methods showed that these 
cortical structures send back projections to the raphe nuclei assuring the substrate for 
feedback control of cortical 5-HT release46. These experiments clearly demonstrated that 5-
HT in the PFC represents a major regulator of its function i.e. in conditioned learning, 
working memory and also eating behavior67, 68.  
 
 
The role of the PFC in food intake 
Based on MRI findings, obese participants revealed a lower degree of centrality in the 
middle frontal gyrus compared to normal-weight controls67. Neural impulse control in the 
dorsolateral prefrontal cortex (DLPFC) measured with fMRI directly after a diet has been 
associated with real-world diet success in obese individuals across enlarged time frames69. 
Furthermore, the study of Le et al. demonstrated that obese women exhibit less activation in 
the left DLPFC in response to a meal than lean or formerly obese women70. Moreover, it has 
been shown that transcranial direct current stimulation (tDCS) modifies cortical excitability 
and thus facilitates improved control of eating71. Participants consumed less kilocalories/day 
(kcal/d), fewer kcal from soda as well as fat. Those participants lost more weight during 
anodal v. cathodal tDCS. Taken together the results indicate a role for the PFC especially 
the (left) DLPFC in the top-down inhibitory control of food intake, dysregulation of which is 
associated with obesity. 
 
The association between central 5-HT transporter (5-HTT) availability and obesity 
5-HTT regulates serotonergic transmission by reuptake or release of 5-HT resulting in 
regulation of extracellular 5-HT concentrations. Drugs that inhibit 5-HTT (which elevate 
synaptic 5-HT), inhibit food intake in both animals60, 72 and humans73, 74, 75.  
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In vivo molecular imaging studies of 5-HTT have been performed to gain insight into 
regulation of 5-HTT availability in distinct brain regions. These studies employ modern brain 
imaging techniques such as PET and single-photon emission computer tomography 
(SPECT) with highly selective radiotracers for many molecular targets including central 
monoamine transmitters. Recently, a PET study in humans applying the 5-HTT selective 
radiotracer[11C]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C] DASB) 
revealed an association between BMI and reduced subcortical (caudate-putamen-thalamus) 
5-HTT availability while other studies did not show a significant difference in central 5-HTT 
binding between highly obese and non-obese controls76 77, 78. By performing a [123I] nor-β-
CIT SPECT study in 16 monozygotic twin pairs, Koskela et al. noticed that twins with a BMI 
higher than their monozygotic co-twins have higher 5-HTT binding in the midbrain79 whereas 
other found a positive association between the 5-HTT availability and BMI in the thalamus80. 
Furthermore, the study of Versteeg et al. investigated the [123I]FP-CIT binding in the 
diencephalon (reflecting 5-HTT) by performing SPECT with insulin-sensitive obese (ISO) 
and insulin-resistant (IRO) obese subjects as well as age-matched lean controls81. In that 
study, 5-HTT binding in the diencephalon was significantly lower in IRO compared to ISO 
individuals81 independently of body weight. No significant difference between lean and 
obese individuals was noticed. Additionally, 5-HTT binding in the hypothalamus tended to be 
reduced in obese versus lean individuals, but was not different between IRO and ISO 
individuals81. The results indicate, that metabolic perturbation linked with obesity 
independently affect 5-HTT binding within the diencephalon81. 
 
Genetics of obesity 
Studies performed on twins indicate that genes account for more than 50% of the variation in 
body mass 82. More than 400 genes have been associated with weight regulation83. In some 
cases of obesity, a relation to single-gene mutations has been described e.g. in the POMC 
gene84, melano-cortin-4 receptor (MC4R) gene85, dopamine D4 receptor (DRD4) gene86, 
peroxisome proliferator-activated receptor y2 (PPARy2) gene87 and the fat mass- and 
obesity associated (FTO) gene88. Moreover, various genetic syndromes have been linked 
with severe obesity, e.g. the Bardet-Biedl syndrome, Prader-Willi syndrome89 and the 
Carpenter syndrome 90. 
Experiments performed in rodent models revealed that mice lacking expression of the CNS 
5-HT synthetic enzyme TPH2 displayed decreased food consumption and body weight48. 
However, further studies with TPH2 knockout mice reported inconsistent results91-94. It has 
been shown that genetic manipulation of 5-HTT gene thereby enhancing 5-HT results in 
inhibition of feeding39. In line with this, the absence of 5-HT reuptake into presynaptic 
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terminals elevated synaptic concentrations of 5-HT, and elevated extracellular 5-HT levels 
have been found in 5-HTT knock-out mice95. However, mice lacking 5-HTT exhibit an adult-
onset obesity phenotype possibly owing to peripheral 5HT signaling96, 97. Similarly, in 
humans, several studies have indicated that obese and overweight individuals exhibit 
decreased expression of the gene that encodes the 5-HTT98, 99. 
The functional polymorphism 5-HTTLPR in the promoter region of SLC6A4 is located on 
chromosome 17q11.1–17q12100. 5-HTTLPR represents a 43-bp in 5-HTT insertion/deletion 
polymorphism in the promoter region upstream of the 5-HTT coding sequence of the 
SLC6A4 gene and results in a short (S) and a long (L) allelic variant that alters SLC6A4 
transcription and the magnitude of 5-HTT function101, 102. L and S variants of 5-HTTLPR 
differentially modulate transcription of SLC6A4. Carriers of the homozygous L-allele variant 
reveal elevated concentrations of 5-HTT mRNA and express nearly twofold greater 5-HT 
reuptake compared to S-allele carriers. Consequently, the existence of S-allele lowers the 
transcriptional activity of 5-HTTLPR leading to diminished 5-HTT expression and 5-HT 
reuptake. However, PET studies using the highly 5-HTT-selective radiotracer [11C] DASB 
revealed inconsistent results on 5-HTTLPR genotype and in vivo 5-HTT availability in the 
human brain103-106. For example, the study of Murthy et al. revealed that 5-HTTLPR does not 
affect the 5-HTT availability103. In contrast, the study of Reimold et.al demonstrated that 
homozygous L-allele carrier display increased expression of 5-HTT in the midbrain 
compared to carriers of at least one S allele106.  
Furthermore, 5-HTTLPR has been associated with obesity and increased BMI98-100. Here, in 
contrast to the homozygous L-variant, the S-allele of 5-HTTLPR has been linked to 
overweight and seems to be a risk factor allele for obesity98. Moreover, it has been shown 
that the 5-HTTLPR/rs25531 genotype, an A/G single nucleotide polymorphism (SNP) within 
5-HTTLPR that have been known to differentially impact L-allele function, influences reward 
responsiveness107. Here, S-allele carriers showed larger stress-related reduction in reward 
responsiveness relative to L-allele carries107.  
 
Epigenetics of obesity 
Beyond DNA sequence-based genetic variation, and how this shapes individual differences 
in human brain 5-HTT function, complex behavioral traits and related risk for 
psychopathology, non-sequence-based epigenetic variation, such as DNA methylation of 5-
HTTLPR, is likely of significance, but has not yet been explored. 
Methylation plays a major role in controlling gene expression, in particular transcriptional 
silencing of transposable elements, or genomic imprinting108-111. Imprinted genes are 
represented by growth factors or regulators of gene expression that controls growth112. 
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Failure in imprinting often results in obesity due to alteration of expression of growth and 
cellular differentiation factors induced by various genetic events such as translocation, 
inversion, duplication, paternal disomy and hyper/hypo-methylation112. 
The site and tissue specific molecular mechanism behind DNA methylation typically involves 
DNA methyltransferases which transfer a methyl group at position five of the cytosine ring of 
most cytosine-phosphate-guanine (CpG) dinucleotides in the mammalian genome without 
changing the DNA sequence108, 112, 113. This comprises the recruitment of binding proteins 
acting together with histone deacetylases and chromatin remodeling complexes to recognize 
methylated DNA114, 115. Thus, elevated DNA methylation level in a promoter of a gene results 
in heterochromatisation of the chromatin structure followed by silenced or reduced gene 
expression114, 115. 
Recent explorative studies revealed that 5-HTTLPR methylation patterns of different CpG 
loci are a functionally relevant biomarker of reduced in vivo 5-HTT expression116-118 
associated with behavioral outcomes119, 120 since epigenetic mechanisms are thought to 
moderate genetic and environmental risk for mood disorders119. Consistent with human data, 
experiments in rhesus macaques demonstrated that carriers of low-expressing 5-HTTLPR 
alleles revealed higher mean 5-HTT CpG methylation associated with lower 5-HTT 
expression in peripheral blood mononuclear cells119, and higher 5-HTT CpG methylation 
level has been associated with an exacerbation of the effects of early life stress on 
behavioral stress reactivity in infants119. In conclusion, 5-HTT CpG methylation seems to be 
an important modulator of 5-HTT expression in early development and probably contribute to 
the risk of mood disorders observable in “high-risk” 5-HTTLPR carriers119.  
Additionally, DNA methylation in 5-HTTLPR has been increasingly discussed as an 
important risk factor for obesity121. A study performed in monozygotic twin pairs found 
SLC6A4 promoter hypermethylation significantly associated with an increased prevalence of 
obesity122. Furthermore, 5-HTTLPR DNA methylation in the PFC has been described to be a 
highly dynamic process modified by genetic variance and regulated by gene transcription 
due to fast changes of DNA methylation patterns during the prenatal period that slow down 
after birth and continue to slow down with ageing123. 
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Objectives and hypothesis of the present work 
The primary aim of the present study was to investigate whether 5-HTTLPR methylation has 
an impact on in vivo 5-HTT availability in obese and normal-weight individuals. Since 
methylation rates are assumed to be associated with low transcription rates108, 109, 124, we 
hypothesized that elevated methylation rates of 5-HTTLPR results in lower in vivo 5-HTT 
availability. Methylation rates were determined in 14 CpG-loci122 by using the PyroMark 
CpG-assays (Qiagen, Hilden, Germany; see Figure 1) based on the Origene ID 
NM_001045. The assays were designed to capture the CpG sites upstream of the 
transcriptional start site in 5-HTTLPR and are targeted to the antisense sequence of 
SLC6A4125. Second, we investigated whether there is an impact of CpG-associated 5-HTT 
availability on measures of behavioral control in 5-HT dependent regulatory areas of the 
PFC126. To assess reward function, we used the behavioral approach system (BAS) reward 
scale, which is part of the reinforcement sensitivity construct of Gray 127. To account for 
covariates, we studied whether BMI and age have an effect on a possible association 
between CpG and 5-HTT availability. 5-HTTLPR methylation rates were assessed from 
peripheral blood cells as a proxy for central in vivo 5-HTT128-130. 
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Serotonin transporter gene promoter methylation
status correlates with in vivo prefrontal 5-HTT
availability and reward function in human obesity
M Drabe1,2, M Rullmann1,2,3, J Luthardt2, Y Boettcher1,4,5, R Regenthal6, T Ploetz6, GA Becker2, M Patt2, C Schinke1,7, FT Bergh7,
F Zientek1, A Hilbert1,8, A Bresch2, W Fenske1,9, MK Hankir1, O Sabri1,2 and S Hesse1,2
A polymorphism in the promoter region of the human serotonin transporter (5-HTT)-coding SLC6A4 gene (5-HTTLPR) has been
implicated in moderating susceptibility to stress-related psychopathology and to possess regulatory functions on human in vivo
5-HTT availability. However, data on a direct relation between 5-HTTLPR and in vivo 5-HTT availability have been inconsistent.
Additional factors such as epigenetic modiﬁcations of 5-HTTLPR might contribute to this association. This is of particular interest
in the context of obesity, as an association with 5-HTTLPR hypermethylation has previously been reported. Here, we tested the
hypothesis that methylation rates of 14 cytosine–phosphate–guanine (CpG) 5-HTTLPR loci, in vivo central 5-HTT availability as
measured with [11C]DASB positron emission tomography (PET) and body mass index (BMI) are related in a group of 30 obese
(age: 36 ± 10 years, BMI435 kg/m2) and 14 normal-weight controls (age 36 ± 7 years, BMIo25 kg/m2). No signiﬁcant association
between 5-HTTLPR methylation and BMI overall was found. However, site-speciﬁc elevations in 5-HTTLPR methylation rates were
signiﬁcantly associated with lower 5-HTT availability in regions of the prefrontal cortex (PFC) speciﬁcally within the obese group
when analyzed in isolation. This association was independent of functional 5-HTTLPR allelic variation. In addition, negative
correlative data showed that CpG10-associated 5-HTT availability determines levels of reward sensitivity in obesity. Together, our
ﬁndings suggest that epigenetic mechanisms rather than 5-HTTLPR alone inﬂuence in vivo 5-HTT availability, predominantly in
regions having a critical role in reward processing, and this might have an impact on the progression of the obese phenotype.
Translational Psychiatry (2017) 7, e1167; doi:10.1038/tp.2017.133; published online 4 July 2017
INTRODUCTION
The serotonin (5-hydroxytryptamine, 5-HT) transporter (5-HTT) has
a crucial role in regulating emotional and reward processing.1–3
Changes in 5-HTT availability and thus synaptic serotonin levels
have been associated with stress-related diseases such as mental
and metabolic disorders including obesity.4–10
Speciﬁcally, obesity has been associated with reduced
subcortical (caudate–putamen–thalamus) 5-HTT availability11
and increased 5-HT4 receptor availability in the nucleus
accumbens and ventral pallidum,12 regions that are intimately
involved in reward processing. These changes are possibly
compensatory in nature because of reduced brain serotonin
levels,13 which is well known to promote a negative energy
balance through suppression of appetite. The precise mechanisms
however that lead to changes in 5-HTT availability in vivo remain
unclear.
At the genetic level, a 43-bp insertion/deletion polymorphism in
the promoter region upstream of the 5-HTT-coding sequence
(5-HTTLPR) of the SLC6A4 gene has been shown to result in a short
(S) and a long (L) allelic variant that alters SLC6A4 transcription
and the magnitude of 5-HTT function.1,14 As a result, carriers of
the homozygous L-allele variant exhibit elevated concentrations
of 5-HTT mRNA and express nearly twofold greater 5-HT re-uptake
in contrast to S-allele carriers. Consequently, the existence of
S-allele lowers the transcriptional activity of 5-HTTLPR, leading to
diminished 5-HTT expression and 5-HT reuptake. However,
positron emission tomography (PET) studies using the highly
5-HTT-selective radiotracer [11C]-3-amino-4-(2-dimethylamino-
methylphenylsulfanyl)-benzonitrile (DASB) have produced incon-
clusive results on 5-HTTLPR genotype and in vivo 5-HTT availability
in the human brain.15–18
To further strengthen our understanding of how DNA
sequence-based genetic variation shapes individual differences
in human brain 5-HTT function, behavioral traits and related risk
for psychopathology, non-sequence-based epigenetic variation,
that is, DNA methylation of 5-HTTLPR, need to be considered, but
as yet remain relatively unexplored. DNA methylation mainly
occurs at DNA sections where cytosine is succeeded by guanine
(cytosine–phosphate–guanine (CpG) dinucleotides). Site-speciﬁc
changes typically involve DNA methyltransferases transferring a
methyl group to position ﬁve of the cytosine ring of most CpG
dinucleotides in the mammalian genome without affecting the
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DNA sequence.19,20 Recent data have shown a potential link
between epigenetic variation, for example, methylation in CpG-
rich regions of 5-HTTLPR and behavior.21–24 Explorative studies
also revealed that 5-HTTLPR methylation patterns of different CpG
loci are a functionally relevant biomarker of reduced in vivo 5-HTT
expression (assessed from peripheral blood cells)25–27 associated
with behavioral outcomes.24,28 Speciﬁcally, increased 5-HTTLPR
methylation predicted an increased threat-related amygdala
reactivity in vivo and decreased mRNA expression in postmortem
amygdala tissue from a third independent cohort (to gain further
mechanistic insight into the in vivo ﬁndings)29 functionally
coupled with key nodes of the salience network.30
Furthermore, epigenetic variations in 5-HTTLPR are increasingly
being discussed as an important risk factor for obesity.21 In a
monozygotic twin study covering 84 twin pairs, Zhao et al. found
SLC6A4 promoter hypermethylation signiﬁcantly associated with
an increased prevalence of obesity.21 In addition, 5-HTTLPR DNA
methylation in the prefrontal cortex (PFC) has been described to
be a highly dynamic process modiﬁed by genetic variance and
regulating gene transcription due to fast changes of DNA
methylation patterns during the prenatal period that slows down
after birth and continues to slow down with aging.31 In the PFC,
serotonin represents a major modulator of its function.32 The PFC
exhibits a dense expression of serotonergic receptors and
represents a region of serotonergic innervation.32 Here, 5-HT1A,
5-HT2A and 5-HT3A receptors are selectively expressed in distinct
populations of pyramidal neurons and inhibitory interneurons.32
This is of particular interest, as the PFC has also been linked with
obesity as shown by resting-state and task-related functional
magnetic resonance imaging studies.33–35 Thus, a lesser degree of
centrality in the left middle frontal gyrus has been demonstrated,
suggesting the important role of the middle frontal gyrus in the
pathophysiology of obesity.33
5-HT has also been discussed as a fundamental mediator of
emotional, motivational and cognitive aspects of reward
representation.36 For instance, Nakamura et al. demonstrated in
non-human primates that, unlike dopamine-containing neurons of
the substantia nigra, serotonin-containing neurons of the dorsal
raphe nucleus encode the value of a received fruit juice reward.37
Moreover, the study of Choi et al. revealed interactions between
reward and threat processing in regions of human PFC, that is, the
middle frontal gyrus, but also in other distinct brain regions,38 that
is, the nucleus accumbens, a key neural substrate in the reward
system since its involvement in natural (that is, food)
reinforcement.39
No studies have been conducted so far comparing 5-HTTLPR
methylation and in vivo 5-HTT availability in the PFC, in particular,
in human obesity in the context of reward processing. The primary
aim of the present study was, therefore, to investigate whether 5-
HTTLPR methylation has an impact on in vivo 5-HTT availability in
obese and normal-weight individuals. As methylation rates are
assumed to be associated with low transcription rates,19,40,41 we
hypothesized that elevated methylation rates of 5-HTTLPR result
in lower in vivo 5-HTT availability. Second, we investigated
whether there is an impact of CpG-associated 5-HTT availability
on measures of behavioral control in 5-HT-dependent regulatory
areas of the PFC.42 To assess reward function, we used the
behavioral approach system (BAS) reward scale as our own
previous study data indicated that 5-HTT availability is associated
with levels of BAS reward determined by questionnaire score
scales in the PFC. Finally, to account for covariates, we studied
whether body mass index (BMI) and age have an effect on a
possible association between CpG and 5-HTT availability. 5-
HTTLPR methylation rates were assessed from peripheral blood
cells as a proxy for central in vivo 5-HTT.43–45
MATERIALS AND METHODS
Study population
The study cohort consisted of 44 non-depressed volunteers (Caucasians)
covering an age range of 21–59 years with a mean age of 36 ± 9 years and
a BMI range of 19–54 kg/m2. This included 14 study participants with a
BMIo27 kg/m2 (mean age 36± 7 years, 9 female) and 30 obese
participants with a BMI435 kg/m2 (mean age 36± 10 years, 20 female)
as previously described.46 All participants gave their written informed
consent.
Study participants were clinically examined by a physician and assessed
for the mental illness via structured interview by a psychiatrist. Exclusion
criteria comprised present or past alcohol abuse and/or drug abuse,
current or past neurological or psychiatric diseases, epilepsy, migraine,
epileptic seizures in their previous medical history (or in the family history),
neurosurgical interventions in the past, pregnancy or other medical
conditions as well as drugs that may alter or inﬂuence brain function (for
example, antidepressants). Study participants were running an Obesity
program in the Ambulance of the IFB AdiposityDiseases in Leipzig,
Germany, which includes metabolic status before selecting patients for
studies. They were investigated regarding type I or insulin-dependent type
II diabetes. Patients with diabetes requiring insulin therapy as well as those
with poorly controlled diabetes (HbA1c47%) were excluded from the
study. Exclusion criteria also covered contraindications for magnetic
resonance imaging (for example, implanted ferromagnetic devices,
claustrophobia), which was performed to exclude structural lesions such
as traumatic brain injuries and stroke. Magnetic resonance imaging
included sequences for anatomical data co-registration (3 T, Siemens,
Erlangen, Germany; T1-weighted 3D magnetization prepared rapid
gradient echo; time of repetition: 2300 ms, time of echo: 2.98 ms, 176
slices, ﬁeld of view: 256× 240 mm, voxel size: 1 × 1 × 1 mm).
On the day of PET imaging, the extent of depressive symptoms was
rated using the Beck Depression Inventory.47 On the same day prior to PET
scanning, typical laboratory parameters, for example, glucose (mg dl− 1),
insulin (mg dl− 1) and Hba1c (mmol l
− 1), were assessed and peripheral
blood samples for genotyping were collected and immediately refriger-
ated at − 80 °C.
The study was conducted in accordance with the Helsinki Declaration
and approved by the ethics committee of the Medical Faculty of the
University of Leipzig registered under the number 206-10-08032010 and
the German Bundesamt für Strahlenschutz/Federal Ofﬁce for Radiation
Protection (number Z5-22461-2-2011-002). The study was registered at the
European clinical trial database (EudraCT 2012-000568-32) and the German
Clinical Trials Register (DRKS).
The behavioral inhibition system/behavioral activation system
scales
In addition, the sensitivity to reward and punishment as based on the
behavioral inhibition system/behavioral activation system (BIS/BAS)
scales48 was measured as a relevant personality factor in the context of
BMI.49 This self-report questionnaire consists of 20 items designed to
assess the responsiveness of BAS and BIS personality characteristics. The 7-
item BIS scale measures the reactivity of the aversive motivational system,
whereas the13-item BAS scale measures reactivity of the appetitive
motivational system. The BAS scale can be divided into three subscales:
drive, fun-seeking and reward.
PET image acquisition
The 5-HTT selective, carbon-11-labeled radiotracer was applied as
previously described.7,46 After 10 min transmission scan from three 68Ga
sources for attenuation correction and intravenous bolus injection (90 s) of
484 ± 10 MBq [11C]DASB a dynamic PET scan was performed to collect
emission data by using an ECAT EXACT HR+ scanner (Siemens; intrinsic
resolution at the center 4.3 mm (full width at half maximum, FWHM), axial
resolution: 5–6 mm, ﬁeld of view: 15.5 cm, 3–4 mm FWHM) in a 3D mode
over 90 min (23 frames: 4 × 0.25, 4 × 1, 5 × 2, 5 × 5, 5 × 10 min). Data were
iteratively reconstructed (10 iterations, 16 subsets) in transverse image
series (63 slices, 128 × 128 matrix, voxel size 2.6 × 2.6 × 2.4 mm) with a
Hann ﬁlter (cutoff 4.9 mm).
Imaging data processing
Individual magnetic resonance imaging data sets of the participants were
spatially reoriented onto a standard brain data set, deﬁned by the anterior
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and posterior commissure (AC-PC), lie on a straight horizontal line similar
to AC-PC orientation—using PMOD software (version 3.4, PMOD Technol-
ogies, Zurich, Switzerland). 5-HTT binding potential (BPND) maps were
generated by using the multilinear reference tissue model (MRTM2).42 The
raphe dorsalis was used as receptor-rich region. The cerebellar cortex
(without vermis) referred as reference region.50 The estimation of k2
occurred individually.
Genotyping of 5-HTTLPR
To determine the bi-allelic status, genomic DNA was extracted from 1 ml of
a 5–10 ml sample of peripheral blood with ethylenediaminetetraacetic acid
as anticoagulant. Isolation steps were performed using pegGold DNA
Mini kit (pegLab, Erlangen, Germany) according to the manufacturer’s
instructions. 5-HTTLPR gene polymorphism study was performed with
standardized polymerase chain reaction ampliﬁcation procedure.51 Utilized
primer sequences were 5’-GAGGGACTGAGCTGGACAAC-3’ and 5’-GCAGCA
GACAACTGTGTTCATC-3’, yielding to a product length of ~ 620 bp for the
L-allele, and 583 bp for the S-allele. Used primers were purchased from
Invitrogen (Paisley, UK).
DNA methylation analysis by quantitative bisulﬁte pyrosequencing
Methylation rates were determined including 14 CpG-loci21 by using the
PyroMark CpG-assays (Qiagen, Hilden, Germany; see Figure 1) based on the
Origene ID NM_001045. The assays were designed to capture the CpG sites
in the promoter region upstream of the transcriptional start site and are
targeted to the antisense sequence of SLC6A4.51 Genomic DNA was
extracted by DNeasy Blood & Tissue Kit (Qiagen) from peripheral blood
leukocytes. Bisulﬁte conversion was performed by using 500 ng genomic
DNA using Qiagen Epitect Bisulﬁte Kit according to the manufacturer’s
protocol. Pyrosequencing was executed using pyrosequencing instrument
technology (Qiagen). Pyrogram analyses occurred via PyroMark Q24
software (version 2.0.6, Qiagen). Each subject sample was independently
replicated on different plates. At every CpG locus, the mean percentage
(%) of methylation was calculated.
Data analysis
A voxel-wise statistical analysis of BPND maps was performed using SPM8
(Statistical Parametric Mapping, Wellcome Department of Cognitive
Neurobiology, UK) implemented in Matlab 7.13 (The MathWorks, Natick,
MA, USA). Motion correction was performed as implemented in SPM. The
mean images (frames 1–13, 0–15 min) were used to determine the
spatially normalization matrix on the SPM8-integrated PET template and
subsequently applied to the BPND maps. Brain regions were denoted in
accordance to the nomenclature by the LONI Probabilistic Brain Atlas
(LPBA40).52 Here, only regions of the PFC by using a prefrontal mask were
considered (that is, the left inferior frontal gyrus, the right middle frontal
gyrus, the left middle frontal gyrus and the right inferior frontal gyrus
(Supplementary Table S1)). Smoothing was performed with an 8 mm
FWHM Gaussian ﬁlter. Group differences in BPND maps between LL and S
+Carriers were tested voxelwise in SPM using a two-sampled t-test with
methylation rate as nuisance variable and predeﬁned prefrontal mask as
explicit mask. A one-sample t-test was used to test for correlation of
parametric BPND images and methylation rate throughout the predeﬁned
prefrontal mask in SPM. We report effects for clusters of voxels exceeding a
peak level threshold of Po0.001 (uncorrected) and a cluster size threshold
of Po0.05, family-wise error-corrected. For the voxelwise correlation
analysis, the ﬁrst eigenvariate of signiﬁcant clusters was extracted and
correlated with BAS questionnaire scores. The ﬁrst eigenvariate represents
the weighted mean of BPND in clusters deﬁned by their signiﬁcant
correlation to the CpG locus methylation rate.
Statistical analysis
In SPSS (version 21, SPSS, IBM, Chicago, IL, USA), all obtained data were
tested for normal distribution through application of Shapiro–Wilk test.
Unpaired t-test was performed in the analysis of differences observed
between groups (that is, comparison on CpG loci methylation rates
between 5-HTTLPR variants, Table 1). To test for correlations between the
5-HTT BPND and other investigated parameters (for example, BAS reward,
BAS fun, BAS drive, BIS and BMI), two-sided Pearson's correlation analysis
was applied. Bonferroni correction was carried out to correct for multiple
comparisons.
RESULTS
Sample characteristics
Application of Shapiro–Wilk test revealed that all obtained data
were normally distributed (P⩾ 0.05).
Effects of 5-HTTLPR genotypes on demographics,
neuropsychological scores and methylation rates
Subjective parameters stratiﬁed for 5-HTTLPR genotypes of all
study participants demonstrated similar data distribution: homo-
zygous LL and S+ carriers did neither signiﬁcantly differ in
demographics, neuropsychological scores nor in their methylation
rates in the distinct CpG loci (Table 1). Voxel-wise SPM genotype
group comparison (LL versus S+Carriers) with CpG 10 loci as
nuisance covariate revealed no signiﬁcant differences, neither in
obese nor in normal-weight individuals (data not shown).
Effects of methylation on BPND in obese versus normal-weight
individuals
In SPM analysis, we found 5-HTTLPR methylation rates in locus
CpG10 to be signiﬁcantly negatively correlated with BPND across
Figure 1. Exposure of SLC6A4 gene promoter region for bisulﬁte sequencing analysis. Analyzed cytosine–phosphate–guanine (CpG) sites are
bolded and underlined. Assay design was based on the Origene ID NM_001045.
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clusters of PFC: left inferior frontal gyrus, right middle frontal
gyrus, left middle frontal gyrus and right inferior frontal gyrus
(Figures 2 and 3 and Supplementary Information S1). The results
were found only in obese but not in normal-weight individuals. All
other investigated CpG loci showed no signiﬁcant correlations
with BPND in clusters of PFC in obese or normal-weight individuals.
Effects of BPND-associated CpG10 methylation rate on reward
sensitivity
We investigated whether BPND-associated CpG10 methylation rate
correlates with reward as well as covariates, that is, BMI and age
by application of two-sided Pearson's correlation analysis. As
presented in Figure 2 and Table 2, BPND in PFC clusters associated
to methylation of locus CpG10 correlated negatively with BAS
reward score (r=− 0.64, P= 0.001) in the obese cohort. However,
no signiﬁcant correlations were found between BPND in PFC
clusters associated to methylation of locus CpG10 and other
investigated covariates, that is, age, BMI, BAS Fun Seeking, BAS
Drive as well as BIS (Table 2).
DISCUSSION
The present study demonstrated that in vivo 5-HTT availability in
the PFC represented by the left inferior frontal gyrus, the right
middle frontal gyrus, the left middle frontal gyrus and the right
inferior frontal gyrus negatively associated with the rate of
methylation in locus CpG10 of the 5-HTT gene promoter. These
ﬁndings were observed in obese but not in normal-weight
individuals.
Table 1. Characteristics of participants and comparison on CpG loci
methylation rates between 5-HTTLPR variants (n= 44)
LL S+ P-value
Characteristics of participants
n 21 23 (2)
Age (years) 35.3± 8.8 37.4± 9.8 0.47a
Weight (kg) 105.1± 28.1 104.6± 32.9 0.96a
BMI (kg/m2) 35.5± 8.8 35.1± 10.9 0.88a
BDI 7.4± 6.5 7.5± 7.2 0.96a
Sex (female/male) 16/7 15/6 1b
Activity applied (MBq) 483.0± 12.5 487.2± 7.6 0.35a
BAS fun 11.9± 2.3 11.1± 1.4 0.19a
BAS reward 17.1± 2.2 16.1± 1.9 0.11a
BAS drive 12.9± 1.8 12.6± 2.0 0.53a
BIS 20.1± 3.1 18.0± 3.6 0.05a
CpG loci methylation rates
CpG1 2.4± 0.3 2.4± 0.3 0.62a
CpG2 3.5± 0.5 3.5± 0.6 0.98a
CpG3 1.6± 0.3 1.6± 0.2 0.84a
CpG4 2.0± 0.4 1.8± 0.3 0.08a
CpG5 3.0± 0.6 2.7± 0.5 0.18a
CpG6 2.9± 1.0 2.8± 0.6 0.81a
CpG7 4.7± 0.7 4.7± 0.4 0.80a
CpG8 4.6± 1.0 4.7± 0.5 0.77a
CpG9 3.3± 0.7 3.4± 0.4 0.57a
CpG10 2.2± 0.5 2.1± 0.4 0.45a
CpG11 3.3± 0.5 2.9± 0.4 0.03c
CpG12 2.7± 0.6 2.6± 0.3 0.81a
CpG13 2.4± 0.5 2.6± 0.4 0.19a
CpG14 7.0± 1.5 6.8± 1.3 0.67a
Abbreviations: BAS, behavioral approach system; BDI, Beck Depression
Inventory; BIS, behavioral inhibition system; BMI, body mass index; CpG,
cytosine–phosphate–guanine; LL, homozygous L carriers; S+, homozygous
and heterozygous S carriers. Allele distribution was in Hardy–Weinberg
equilibrium (Pearson Χ2-test). The number in brackets in S+ indicates the
number of homozygous S-carriers. Values represent mean± s.d. aStudent’s
t-test . bFisher’s exact test . cDid not survive correction for multiple testing.
Figure 2. Signiﬁcant correlations between the mean binding potential (BPND) deﬁned by CpG10 methylation rates (unitless, y axis) and
parameters such as: left panel: BAS reward and right panel: methylation rate measured in percent (%) of obese individuals (n= 30) in the
prefrontal cortex (PFC). r, Pearson product–moment correlation coefﬁcient; Po0.05 (signiﬁcant). BAS, behavioral approach system; CpG, CpG,
cytosine–phosphate–guanine.
Figure 3. SPM8 projections superimposed on representative MRI
indicating regions of the PFC52 with signiﬁcant negative correlation
between in vivo BPND and methylation of locus CpG10 (Po0.001
uncorrected on peak level and Po0.05 FWE on cluster level, n= 30).
For corresponding Montreal Neurological Institute coordinates
see Supplementary Table 1. BPND, binding potential; CpG, cyto-
sine–phosphate–guanine; FWE, family-wise error; MRI, magnetic
resonance imaging; PFC, prefrontal cortex.
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The present study was intended to detect changes in the in vivo
5-HTT availability in a cohort of highly obese participants and in
non-obese cohorts. We tried to avoid covariates in a small sample
size as reported in our previous study.46 Participants were
investigated regarding metabolic status in order to exclude those
with type I or insulin-dependent type II diabetes or with poorly
controlled diabetes in general (HbA1c 47%). Thus, we could
avoid the possibility that the studied relationship between
5-HTTLPR methylation rates may be even higher correlated with
the 5-HTT availability than in the presently studied group.
Association of epigenetic modiﬁcation near the 5-HTT-coding
gene might explain the only modest effect size of the 5-HTTLPR
genotype and inconsistent reports on allelic variation in 5-HTT
function.53 We were also not able to conﬁrm a signiﬁcant interac-
tion between genotypic variance within 5-HTTLPR and in vivo
5-HTT availability46 in both groups, normal-weight and obese
individuals.
The process of DNA methylation is known to result in stable
gene repression.19,40 Our ﬁnding of elevated DNA methylation
rates within 5-HTTLPR together with lower in vivo 5-HTT availabi-
lity would be in line with the speciﬁc molecular genetic effects
mediated by DNA methylation.19
DNA methylation is also determined by genetic variation.54,55
Accordingly, the epigenetic effects in our study seem to be
independent of (and stronger than) the effects of genotypic
variance of 5-HTTLPR.29,56
In contrast to the study of Zhao et al. that showed that
methylation rate of 5-HTTLPR is positively correlated with BMI,21
we were not able to demonstrate a signiﬁcant correlation
between 5-HTTLPR methylation and BMI. This could be explained
by the fact that this relation follows a nonlinear curve with
signiﬁcant association only in the highly obese. Similar nonlinear
or quadratic relationships have been described for other biological
markers such as the central dopamine D2 receptor availability57 or
for the central 5-HTT together with 5-HT2A receptors
58 in human
obesity. Instead, we found a negative relationship between
methylation rates of 5-HTTLPR, in vivo 5-HTT availability in the
PFC and the BAS reward subscale as a measure for the sensitivity
to reward. This could ﬁt in a model, as it has been proposed for
the association between BMI and BAS reward with a quadratic
curve indicating high reward sensitivity at moderate-to-high BMI
levels.57
The ﬁndings of our analysis might support a link between the
neurobehavioral effects of changes in modiﬁcations of the
5-HTTLPR and an enhanced sensitivity to motivationally and/or
emotionally relevant environmental stimuli predicting reward. An
important modulatory role in reward processing for 5-HTT was
found in knockout mice in which disruptions of the development
of the reward system59 and interference with reward-based
learning were found.60 For instance, it has been shown that
5-HTTLPR/rs25531 genotype, an A/G single-nucleotide polymorphism
(SNP) within the 5-HTTLPR that have been known to have a
differential impact on L allele function, inﬂuences reward
responsiveness.61 S-allele carriers showed larger stress-related
reduction in reward responsiveness relative to L-allele carriers.61
Yet, we did not ﬁnd a signiﬁcant interaction between genotypic
variance of 5-HTTLPR (without investigating o rs25531) in the PFC
and BAS reward scores. Given the signiﬁcant negative correlation
between CpG methylation and in vivo 5-HTT availability with BAS
reward scores, this result furthermore suggests that epigenetic
effects of site-speciﬁc (that is, locus CpG10) DNA methylation
inﬂuence behavioral control in regions of PFC. We assume that
environmental exposure to rewarding or punishing stimuli and
respective behavioral responses will thus have a greater associa-
tion with methylation of 5-HTTLPR as inﬂuenced by genotypic
variance.
In search of arguments for the notable outliers in the signiﬁcant
Pearson's correlations between the mean BPND deﬁned by CpG10
methylation rates and BAS reward, it must be mentioned that the
numbers of the included obese individuals were modest, which
makes the analysis vulnerable to outliers. Therefore, we cannot
exclude that these outliers signiﬁcantly inﬂuence the investigated
parameters such as reward.
In the present study we only focused on the 5-HTT availability in
the PFC. This does not exclude any correlation between 5-HTTLPR
methylation and 5-HTTLPR availability in regions outside the PFC.
In that manner, we did not perform an unbiased whole-brain
analysis since our own previous study showed that 5-HTT
availability determines levels of BAS reward in the PFC such as
the orbitofrontal cortex (unpublished). Thus, we are also not able
to state whether the 5-HTTLPR methylation status varies globally
or locally across different brain regions62,63 and whether this
indicates region-speciﬁc functional specialization.63 It is possible
that this region-speciﬁc functional specialization involves the
distinctive expression of transcription factors that regulate 5-HTT
transcription.64 For instance, mouse midbrain serotonergic neu-
rons selectively express the transcription factor Pet1, which is
required for normal SLC6A4 transcription in this region.64 It might
be speculated that human PFC neurons selectively express a
transcription factor that normally increases 5-HTT expression and
that is competitively displaced by CpG 10 methylation of the 5-
HTT promoter.
Taken together, our ﬁnding of higher site-speciﬁc methylation
of 5-HTTLPR seems to predict decreased 5-HTT availability and,
consequently, a reduction of regional 5-HT re-uptake capacity in
PFC1,29 would be in agreement with previous literature,1,29,56 and
may contribute to an altered cognitive and emotional function in
obesity. However, we cannot conclude from these results that
epigenetic changes associated with molecular changes in the
brain and behavior predisposes obesity since we could neither
ﬁnd a speciﬁc link of CpG-associated 5-HTT availability with BMI
nor have we directly measured gene expression in our study.
LIMITATIONS
Our study has several limitations. First, we investigated peripheral
blood leukocytes, which are commonly employed in SLC6A4
methylation and allelic variation studies on the basis that
peripheral patterns reﬂect central processes.65,66 Prior work has
provided a signiﬁcant correlation between blood and brain
methylomes,43 and the 5-HTT promoter methylation level
measured in peripheral blood cells has been demonstrated to
be associated with central in vivo 5-HT synthesis as detected by
Table 2. Correlations between BPND in PFC clusters associated to
methylation of locus CpG10 and other parameters such as age, BMI,
BAS reward, BAS fun, BAS drive and BIS in the prefrontal cortex of
obese individuals only (n= 30)
CpG10
R P-value
Age − 0.29 0.12
BMI − 0.25 0.19
BAS reward − 0.64 0.001
BAS fun − 0.07 0.72
BAS drive − 0.34 0.08
BIS − 0.02 0.93
Abbreviations: BAS, behavioral approach system; BIS, behavioral
inhibition system; BMI, body mass index; BPND, binding potential;
CpG, cytosine–phosphate–guanine; PFC, prefrontal cortex. r= Pearson
product–moment correlation coefﬁcient; bold values indicate Po0.05.
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dedicated PET.45 Moreover, studies investigating a comparison
between both platelet and neuronal 5-HTT regulation are rare and
inconsistent results exist concerning functional activity of 5-HTT.
Second, the sample size of our study, in particular of normal-
weight controls (although carefully matched for any variables),
was modest: suitable for a PET study, but with limited statistical
power for genetic analysis. Furthermore, we did not investigate
the 5-HTTLPR/rs25531 genotype, an A/G SNP within the 5-HTTLPR
to estimate the inﬂuence of the rs25531 SNP on the 5-HTTLPR
function. Investigating this genotype would result in a subdivision
of our modest sample size, with the consequence of limited
statistical power.
As this was a pilot study to fuel new hypotheses on an interac-
tion between epigenetics and a distinct molecular target, that is,
the 5-HTT availability in vivo, larger sample sizes are warranted to
identify the main effects of 5-HTT genotype and its modiﬁcation
on in vivo 5-HTT function in psychiatry and/or metabolic research.
Moreover, future studies should be designed to demonstrate the
direct evidence that increased methylation of the 5-HTT (SLC6A4)
gene in the PFC is related to a lower binding of the radiotracer
DASB to the 5-HTT.67–71 This could be performed by using human
autopsy material to gain additionally further mechanistic insights
(that is, by the analysis of 5-HTT mRNA levels in different brain
tissues) to conﬁrm the accordant in vivo ﬁndings.29
CONCLUSION
The present study suggests that epigenetic changes, that is, a DNA
methylation of the 5-HTTLPR, contribute even more to in vivo 5-
HTT availability than 5-HTTLPR itself does. If conﬁrmed, such an
association between distinct (for example, CpG10) loci and
prefrontal 5-HTT might explain differences in reward sensitivity,
thus leading to changes in eating behavior. However, whether
these changes are main drivers of weight gain and obesity and/or
reversible has to be proved.
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Epigenetic modifications as a result of gene and environment interaction might contribute to 
biological changes that influence behavior131-133. The central serotonin (5-hydroxytryptamine, 
5-HT) system with its widespread functional connectivity represents such a candidate 
system since several studies have shown both genetic and epigenetic factors, i.e. a 
polymorphism in the promoter of the serotonin transporter gene (5-HTTLPR) and its 
methylation being associated with stress-related disorders117, 119 and dysfunction of the 
prefrontal network123, 134-137.However, no studies have been performed so far investigating 
the relationship between 5-HTTLPR and 5-HTTLPR methylation, and in vivo 5-HTT 
availability in human obesity, in particular in the prefrontal cortex (PFC) in the context of 
reward-related behavior. The primary aim of our work was therefore to assess whether 5-
 21 
HTTLPR methylation has an impact on in vivo 5-HTT availability in obese and normal-weight 
individuals. Since methylation rates are assumed to be associated with low transcription 
rates108, 109, 124, we hypothesized that elevated methylation rates of 5-HTTLPR results in 
lower in vivo 5-HTT availability. Moreover, whether there is an effect of the cytosine-
phosphate-guanine dinucleotide (CpG) associated 5-HTT availability on measures of 
behavioral control in 5-HT dependent regulatory areas of the PFC was also studied. 
Therefore, methylation rates of 14 CpG 5-HTTLPR loci were assessed together with imaging 
data of PFC using the 5-HTT selective, carbon-11 labelled radiotracer [11C]-3-amino-4-(2-
dimethylaminomethylphenylsulfanyl)-benzonitrile (DASB) in a group of highly obese (n=30; 
age: 36 ± 10 years, BMI > 35 kg/m2) and normal-weight controls (n=14; age 36 ± 7 years, 
BMI < 25 kg/m2).  
In line with the study hypothesis, the results of the study showed that elevated methylation 
rates of 5-HTTLPR were associated with lower in vivo 5-HTT availability, while on the other 
hand, no significant association between 5-HTTLPR methylation and BMI were found. 
Moreover, methylation in locus CpG10 of 5-HTTLPR was significantly negatively associated 
with lower 5-HTT availability in regions of the PFC i.e the left and right inferior frontal gyrus 
known to regulate behavior. These findings were observed only in the obese group and 
independent of functional 5-HTTLPR allelic variation. Hence, epigenetic modification near 
the 5-HTT coding gene might explain the previous inconsistent reports on allelic variation in 
5-HTT function and should be considered in further studies investigating the influence of 
epigenetic mechanisms on weight gain and obesity136. 
Finally, correlative data analysis revealed a significant negative association between 
methylation rates of 5-HTTLPR, in vivo 5-HTT availability in the PFC and the behavioral 
approach system reward scale (BAS) as a measure for the sensitivity to reward. This finding 
suggests that epigenetic effects of site-specific DNA methylation i.e. methylation of locus 
CpG10 of the 5-HTT gene in regions of PFC influence behavioral control.  
In conclusion, the results of the study indicate that epigenetic changes such as DNA 
methylation of the 5-HTTLPR contribute to the in vivo 5-HTT availability even more than 
genetic variations, i.e. of the 5-HTTLPR alone. This includes regions, which play an 
important role in reward processing. The association between methylation of 5-HTTLPR, in 
vivo 5-HTT availability and BAS reward observed in this study suggest a potential 
mechanism in human obesity that is of interest for further studies such combining PET 
molecular imaging and epigenetic measures linked to behavioral sciences.  
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 I 
Appendices 
Glossary 
[11C]DASB   [11C]-3-Amino-4-(2-Dimethylaminomethylphenylsulfanyl)-Benzonitrile 
5,7 DHT   5,7-dihydroxytriptamine 
5-HT   5-Hydroxytryptamine, Serotonin 
5-HTT   Serotonin Reuptake Transporter 
5-HTP   5-Hydroxytryptophan 
5-HTTLPR   Serotonin-Transporter-Linked Polymorphic Region  
 
Arc   Arcuate nucleus 
BAS   Behavioral approach system reward scale 
BMI   Body Mass Index 
CpG   Cytosine-phosphate-guanine dinucleotides 
DA   Dopamine pathway 
DLPFC   dorsolateral prefrontal cortex  
DRD4   Dopamine receptor D4  
FTO   fat-mass-and obesity associated gene 
GABA-A   Gamma-aminobutyric acid receptor A 
HPA   Hypothalamic-pituitary-adrenal axis 
ISO   Insulin-sensitive obese individuals 
IRO   Insulin-resistant obese individuals 
MC4R   Melanocortin 4 Receptor 
mCPP   m-chlorophenylpiperazine 
MRI    Magnetic Resonance Imaging 
NAcc   nucleus accumbens 
PFC   Medial Prefrontal Cortex 
POMC   Proopiomelanocortin  
PPHRy2   Peroxisome proliferators-activated receptor y2 gene  
PVN   Paraventricular nucleus 
SLC6A4   5-Hydroxytryptamine (Serotonin) Transporter 
SPECT   Single Photon Emission Tomography 
TPH   Tryptophan hydroxylase 
tDCS   transcranial direct current stimulation 
WHO   World Health Organization 
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